Ikena Oncology Discontinues Clinical IK-930 Program
DENVER, Colo., May 29, 2024 (247marketnews.com)- Ikena Oncology, Inc. (Nasdaq:IKNA) is discontinuing its clinical IK-930 program to focus on clinical development of IK-595. Ikena finished the first quarter with $157.3 million, which it plans on using to fund operations and explore strategic options to maximize shareholder value
“Ikena is dedicated to thoughtfully putting our capital to work towards impactful treatments for patients, and in doing so building value for our shareholders. Together with our board of directors, we made the difficult decision to wind down the IK-930 program. Going forward, we believe that IK-930’s profile may enable combination opportunities with other targeted agents through partnerships,” commented Ikkkena’s CEO, Mark Manfredi, Ph.D. “Our MEK-RAF molecular glue, IK-595, continues to progress rapidly in the clinic with encouraging early PK and PD data which supports a potentially differentiated therapeutic index. This is key to treating the broad population of patients suffering from RAS and RAF mutant cancers where other MEK inhibitors have failed.”
Ikena’s Chief Financial Officer, Jotin Marango, M.D., Ph.D., commented, “Ikena is in a strong position to create value through multiple avenues. We have been diligent with our capital expenditure, fortifying a cash position that may unlock new strategic opportunities for the company, in addition to the parallel partnership potential of our pipeline.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (IKNA)
- Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
- 24/7 Market News Snapshot 15 July, 2025 – Ikena Oncology, Inc. Common Stock (NASDAQ:IKNA)
- Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
- 24/7 Market News Snapshot 23 December, 2024 – Ikena Oncology, Inc. Common Stock (NASDAQ:IKNA)